BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 23210876)

  • 1. MISAGO 2: one-year outcomes after implantation of the Misago self-expanding nitinol stent in the superficial femoral and popliteal arteries of 744 patients.
    Schulte KL; Kralj I; Gissler HM; Bagnaschino LA; Buschmann I; Pernès JM; Haage P; Goverde P; Beregi JP; Válka M; Boudny J; Geibel T; Velkoborsky M; Zähringer M; Paetzel C; Fanelli F; Müller-Hülsbeck S; Zeller T; Langhoff R
    J Endovasc Ther; 2012 Dec; 19(6):774-84. PubMed ID: 23210876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial.
    Laird JR; Jain A; Zeller T; Feldman R; Scheinert D; Popma JJ; Armstrong EJ; Jaff MR;
    J Endovasc Ther; 2014 Apr; 21(2):202-12. PubMed ID: 24754279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.
    Laird JR; Katzen BT; Scheinert D; Lammer J; Carpenter J; Buchbinder M; Dave R; Ansel G; Lansky A; Cristea E; Collins TJ; Goldstein J; Cao AY; Jaff MR;
    J Endovasc Ther; 2012 Feb; 19(1):1-9. PubMed ID: 22313193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force.
    Goltz JP; Ritter CO; Kellersmann R; Klein D; Hahn D; Kickuth R
    J Endovasc Ther; 2012 Jun; 19(3):450-6. PubMed ID: 22788900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
    J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.
    Laird JR; Yeo KK; Rocha-Singh K; Das T; Joye J; Dippel E; Reddy B; Botti C; Jaff MR
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):852-9. PubMed ID: 22422738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation.
    Rocha-Singh KJ; Beckman JA; Ansel G; Lyden SP; Schneider P; Mehta M; Dake M; Mullin CM; Jaff MR;
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1250-1256. PubMed ID: 28303688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Pearl G; Theune B; Black S
    J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries.
    Yang X; Lu X; Li W; Huang Y; Huang X; Lu M; Jiang M
    J Vasc Surg; 2014 Aug; 60(2):362-8. PubMed ID: 24680242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions.
    Dick P; Wallner H; Sabeti S; Loewe C; Mlekusch W; Lammer J; Koppensteiner R; Minar E; Schillinger M
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1090-5. PubMed ID: 19859954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial.
    Nasser F; Kambara A; Abath C; Cavalcanti D; Barros I; Pires N; Rivera M; Neser A; Ingrund J; Burihan M; Silveira P; Galego G; Bortoluzzi C; Franklin R; Bosiers M; Deloose K; Razuk A; Caffaro R; Karakhanian WK; Park J; Lopes C; Pinto D; Bez L; Lopes R; Mourão A; Kleinsorge G
    J Cardiovasc Surg (Torino); 2017 Jun; 58(3):409-415. PubMed ID: 25731858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.
    Geraghty PJ; Mewissen MW; Jaff MR; Ansel GM;
    J Vasc Surg; 2013 Aug; 58(2):386-95.e4. PubMed ID: 23676191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary stenting of the superficial femoral and popliteal artery.
    Dearing DD; Patel KR; Compoginis JM; Kamel MA; Weaver FA; Katz SG
    J Vasc Surg; 2009 Sep; 50(3):542-7. PubMed ID: 19540706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.